Literature DB >> 11051284

Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications.

F Chiarelli1, A Spagnoli, F Basciani, S Tumini, A Mezzetti, F Cipollone, F Cuccurullo, G Morgese, A Verrotti.   

Abstract

AIMS: To evaluate serum levels of vascular endothelial growth factor (VEGF) in a large group of children, adolescents and young adults with Type 1 diabetes mellitus to investigate whether increased VEGF concentrations are associated with long-term glycaemic control and microvascular complications.
METHODS: The study involved 196 patients with Type 1 diabetes mellitus (age range 2-24 years, onset of diabetes before the age of 12 years, duration of disease longer than 2 years), without clinical and laboratory signs of microvascular complications; they were divided into three groups (group 1 - n = 37, age < 6 years; group 2 - n = 71, age 6-12 years; group 3 - n = 88, age > 12 years). Fifty-three adolescents and young adults (age 16.1-29.7) with different grades of diabetic retinopathy and microalbuminuria were also selected (group 4). A total of 223 healthy controls were matched for age and sex with each group of patients with diabetes mellitus.
RESULTS: VEGF serum levels were significantly increased in pre-school and pre-pubertal children with diabetes as well as in pubertal patients compared to controls. VEGF concentrations were markedly increased in adolescents and young adults with microvascular complications compared with both healthy controls and diabetic patients without retinopathy or nephropathy. Multivariate analysis showed that elevation of VEGF in serum was an independent correlate of complications. One-year mean HbA1c values were significantly correlated with VEGF concentrations (r = 0.372; P < 0.01). Children with HbA1c levels greater than 10% had significantly higher VEGF concentrations when compared with matched patients whose HbA1c levels were lower than 10%. In poorly controlled diabetic children (HbA1c > 10%), long-term (2 years) improvement of glycaemic control (aiming at HbA1c < 7%) resulted in a significant reduction of VEGF levels.
CONCLUSIONS: VEGF serum concentrations are increased in prepubertal and pubertal children with diabetes. Glycaemic control influences VEGF serum levels. Severity of microvascular complications is associated with marked increase of VEGF concentrations in the serum of these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051284     DOI: 10.1046/j.1464-5491.2000.00350.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  34 in total

Review 1.  Angiogenesis in diabetes and obesity.

Authors:  Rui Cheng; Jian-xing Ma
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

2.  The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus.

Authors:  Abdolrahim Nikzamir; Alireza Esteghamati; Amir Abbas Hammedian; Touraj Mahmoudi
Journal:  Mol Biol Rep       Date:  2011-05-12       Impact factor: 2.316

3.  Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis.

Authors:  J Todd Kuenstner; William Chamberlin; Saleh A Naser; Michael T Collins; Coad Thomas Dow; John M Aitken; Stuart Weg; Grzegorz Telega; Kuruvilla John; David Haas; Torsten M Eckstein; Maher Kali; Christine Welch; Thomas Petrie
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Molecular and pathological studies in the posterior interosseous nerve of diabetic and non-diabetic patients with carpal tunnel syndrome.

Authors:  Moaz A Mojaddidi; Mohammed S Ahmed; Razwan Ali; Maria Jeziorska; Ahmed Al-Sunni; Niels O B Thomsen; Lars B Dahlin; Rayaz A Malik
Journal:  Diabetologia       Date:  2014-05-28       Impact factor: 10.122

Review 5.  Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials.

Authors:  Nader Rahimi
Journal:  Exp Eye Res       Date:  2006-05-19       Impact factor: 3.467

6.  Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats.

Authors:  A A Bosco; A C Lerario; R F Santos; B L Wajchenberg
Journal:  Diabetologia       Date:  2003-11-04       Impact factor: 10.122

7.  Intensive insulin therapy protects the endothelium of critically ill patients.

Authors:  Lies Langouche; Ilse Vanhorebeek; Dirk Vlasselaers; Sarah Vander Perre; Pieter J Wouters; Kristin Skogstrand; Troels K Hansen; Greet Van den Berghe
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 8.  Vascular endothelial growth factor and diabetic nephropathy.

Authors:  Sheldon Chen; Fuad N Ziyadeh
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

9.  Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival.

Authors:  Sherry Lynn Franklin; Robert J Ferry; Pinchas Cohen
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

10.  Comparison of osteoprotegerin and vascular endothelial growth factor in normoalbuminuric Type 1 diabetic and control subjects.

Authors:  A Esteghamati; A Arefzadeh; A Zandieh; M Salehi Sadaghiani; S Noshad; M Nakhjavani
Journal:  J Endocrinol Invest       Date:  2013 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.